Corpus overview


Overview

MeSH Disease

Human Phenotype

Pneumonia (48)

Cough (48)

Fatigue (48)

Fever (46)

Dyspnea (12)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 48
    records per page




    Automatic analysis system of COVID-19 radiographic lung images (XrayCoviDetector)

    Authors: Juan Nicolas Schlotterbeck; Carlos E Montoya; Patricia Bitar; Jorge A Fuentes; Victor Dinamarca; Gonzalo M Rojas; Marcelo Galvez; Andreas Limmer; Jia Liu; Xin Zheng; Thorsten Brenner; Marc M. Berger; Oliver Witzke; Mirko Trilling; Mengji Lu; Dongliang Yang; Nina Babel; Timm Westhoff; Ulf Dittmer; Gennadiy Zelinskyy; Kelly M Schiabor Barrett; Stephen Riffle; Alexandre Bolze; Simon White; Francisco Tanudjaja; Xueqing Wang; Jimmy M Ramirez III; Yan Wei Lim; James T Lu; Nicole L Washington; Eco JC de Geus; Patrick Deelen; H Marike Boezen; Lude H Franke

    doi:10.1101/2020.08.20.20178723 Date: 2020-08-23 Source: medRxiv

    COVID-19 is a pandemic infectious disease MESHD caused by the SARS-CoV-2 virus, having reached more than 210 countries and territories. It produces symptoms such as fever HP fever MESHD, dry cough MESHD cough HP, dyspnea HP dyspnea MESHD, fatigue HP fatigue MESHD, pneumonia HP pneumonia MESHD, and radiological manifestations. The most common reported RX and CT findings include lung consolidation and ground-glass opacities. In this paper, we describe a machine learning-based system (XrayCoviDetector; www.covidetector.net), that detects automatically, the probability that a thorax radiological image includes COVID-19 lung patterns. XrayCoviDetector has an accuracy of 0.93, a sensitivity SERO of 0.96, and a specificity of 0.90.

    A Large-Scale Clinical Validation Study Using nCapp Cloud Plus Terminal by Frontline Doctors for the Rapid Diagnosis of COVID-19 and COVID-19 pneumonia HP pneumonia MESHD in China

    Authors: Dawei Yang; Tao Xu; Xun Wang; Deng Chen; Ziqiang Zhang; Lichuan Zhang; Jie Liu; Kui Xiao; Li Bai; Yong Zhang; Lin Zhao; Lin Tong; Chaomin Wu; Yaoli Wang; Chunling Dong; Maosong Ye; Yu Xu; Zhenju Song; Hong Chen; Jing Li; Jiwei Wang; Fei Tan; Hai Yu; Jian Zhou; Jinming Yu; Chunhua Du; Hongqing Zhao; Yu Shang; Linian Huang; Jianping Zhao; Yang Jin; Charles A. Powell; Yuanlin Song; Chunxue Bai

    doi:10.1101/2020.08.07.20163402 Date: 2020-08-11 Source: medRxiv

    Background The outbreak of coronavirus disease MESHD 2019 (COVID-19) has become a global pandemic acute infectious disease MESHD, especially with the features of possible asymptomatic TRANS carriers TRANS and high contagiousness. It causes acute respiratory distress HP respiratory distress MESHD syndrome and results in a high mortality rate if pneumonia HP is involved. Currently, it is difficult to quickly identify asymptomatic TRANS cases or COVID-19 patients with pneumonia HP pneumonia MESHD due to limited access to reverse transcription-polymerase chain reaction (RT-PCR) nucleic acid tests and CT scans, which facilitates the spread of the disease TRANS at the community level, and contributes to the overwhelming of medical resources in intensive care units. Goal This study aimed to develop a scientific and rigorous clinical diagnostic tool for the rapid prediction of COVID-19 cases based on a COVID-19 clinical case database in China, and to assist global frontline doctors to efficiently and precisely diagnose asymptomatic TRANS COVID-19 patients and cases who had a false-negative RT-PCR test result. Methods With online consent, and the approval of the ethics committee of Zhongshan Hospital Fudan Unversity (approval number B2020-032R) to ensure that patient privacy is protected, clinical information has been uploaded in real-time through the New Coronavirus Intelligent Auto-diagnostic Assistant Application of cloud plus terminal (nCapp) by doctors from different cities (Wuhan, Shanghai, Harbin, Dalian, Wuxi, Qingdao, Rizhao, and Bengbu) during the COVID-19 outbreak in China. By quality control and data anonymization on the platform, a total of 3,249 cases from COVID-19 high-risk groups were collected. These patients had SARS-CoV-2 RT-PCR test results and chest CT scans, both of which were used as the gold standard for the diagnosis of COVID-19 and COVID-19 pneumonia HP pneumonia MESHD. In particular, the dataset included 137 indeterminate cases who initially did not have RT-PCR tests and subsequently had positive RT-PCR results, 62 suspected cases who initially had false-negative RT-PCR test results and subsequently had positive RT-PCR results, and 122 asymptomatic TRANS cases who had positive RT-PCR test results, amongst whom 31 cases were diagnosed. We also integrated the function of a survey in nCapp to collect user feedback from frontline doctors. Findings We applied the statistical method of a multi-factor regression model to the training dataset (1,624 cases) and developed a prediction model for COVID-19 with 9 clinical indicators that are fast and accessible: 'Residing or visiting history in epidemic regions', 'Exposure history to COVID-19 patient', 'Dry cough HP', ' Fatigue HP', 'Breathlessness', 'No body temperature decrease after antibiotic treatment', 'Fingertip blood SERO oxygen saturation<=93%', ' Lymphopenia HP Lymphopenia MESHD', and 'C-reactive protein (CRP) increased'. The area under the receiver operating characteristic (ROC) curve (AUC) for the model was 0.88 (95% CI: 0.86, 0.89) in the training dataset and 0.84 (95% CI: 0.82, 0.86) in the validation dataset (1,625 cases). To ensure the sensitivity SERO of the model, we used a cutoff value of 0.09. The sensitivity SERO and specificity of the model were 98.0% (95% CI: 96.9%, 99.1%) and 17.3% (95% CI: 15.0%, 19.6%), respectively, in the training dataset, and 96.5% (95% CI: 95.1%, 98.0%) and 18.8% (95% CI: 16.4%, 21.2%), respectively, in the validation dataset. In the subset of the 137 indeterminate cases who initially did not have RT-PCR tests and subsequently had positive RT-PCR results, the model predicted 132 cases, accounting for 96.4% (95% CI: 91.7%, 98.8%) of the cases. In the subset of the 62 suspected cases who initially had false-negative RT-PCR test results and subsequently had positive RT-PCR results, the model predicted 59 cases, accounting for 95.2% (95% CI: 86.5%, 99.0%) of the cases. Considering the specificity of the model, we used a cutoff value of 0.32. The sensitivity SERO and specificity of the model were 83.5% (95% CI: 80.5%, 86.4%) and 83.2% (95% CI: 80.9%, 85.5%), respectively, in the training dataset, and 79.6% (95% CI: 76.4%, 82.8%) and 81.3% (95% CI: 78.9%, 83.7%), respectively, in the validation dataset, which is very close to the published AI model. The results of the online survey 'Questionnaire Star' showed that 90.9% of nCapp users in WeChat mini programs were 'satisfied' or 'very satisfied' with the tool. The WeChat mini program received a significantly higher satisfaction rate than other platforms, especially for 'availability and sharing convenience of the App' and 'fast speed of log-in and data entry'. Discussion With the assistance of nCapp, a mobile-based diagnostic tool developed from a large database that we collected from COVID-19 high-risk groups in China, frontline doctors can rapidly identify asymptomatic TRANS patients and avoid misdiagnoses of cases with false-negative RT-PCR results. These patients require timely isolation or close medical supervision. By applying the model, medical resources can be allocated more reasonably, and missed diagnoses can be reduced. In addition, further education and interaction among medical professionals can improve the diagnostic efficiency for COVID-19, thus avoiding the transmission TRANS of the disease from asymptomatic TRANS patients at the community level.

    Older adults TRANS hospitalized with Covid-19: Clinical characteristics and early outcomes from a single center in Istanbul, Turkey 

    Authors: Alpay Medetalibeyoğlu; Naci Senkal; Murat Kose; Yunus Catma; Emine Bilge Caparali; Mustafa Erelel; Mustafa Oral Oncul; Gulistan Bahat; Tufan Tukek

    doi:10.21203/rs.3.rs-47728/v1 Date: 2020-07-22 Source: ResearchSquare

    Objective: Older adults TRANS have been continuously reported to be at higher risk for adverse outcomes of Covid-19. We aimed to describe clinical characteristics and early outcomes of the older Covid-19 patients hospitalized in our center comparatively with the younger patients, and also to analyze the triage factors that were related to the in-hospital mortality of older adults TRANS.Design: Retrospective; observational studySetting: Istanbul Faculty of Medicine hospital, TurkeyParticipants: 362 hospitalized patients with laboratory-confirmed Covid-19 from March 11 to May 11, 2020.Measurements: The demographic information; associated comorbidities; presenting clinical, laboratory, radiological characteristics on admission and outcomes from the electronic medical records were analyzed comparatively between the younger (<65 years) and older (≥65 years) adults TRANS. Factors associated with in-hospital mortality of the older adults TRANS were analyzed by multivariate regression analyses.Results: The median age TRANS was 56 years (interquartile range [IQR], 46-67), and 224 (61.9%) were male TRANS. There were 104 (28.7%) patients ≥65 years of age TRANS. More than half of the patients (58%) had one or more chronic comorbidity. The three most common presenting symptoms in the older patients were fatigue HP atigue/ MESHD myalgia HP yalgia MESHD(89.4%), d ry cough MESHD cough HP (72.1%), and fever HP ever MESHD(63.5%). Cough HP and fever HP ever MESHDwere significantly less prevalent in older adults TRANS compared to younger patients (p=0.001 and 0.008, respectively). Clinically severe pneumonia HP neumonia MESHDwas present in 31.5% of the study population being more common in older adults TRANS (49% vs. 24.4%) (p<0.001). The laboratory parameters that were significantly different between the older and younger adults TRANS were as follows: the older patients had significantly higher CRP, D-dimer, TnT, pro-BNP, procalcitonin levels, higher prevalence SERO of lymphopenia HP ymphopenia, MESHD neutrophilia HP, increased creatinine, and lower hemoglobin, ALT, albumin level (p<0.05). In the radiological evaluation, more than half of the patients (54.6%) had moderate-severe pneumonia HP neumonia, MESHD which was more prevalent in older patients (66% vs. 50%) (p=0.006). The adverse outcomes were significantly more prevalent in older adults TRANS compared to the younger patients (ICU admission, 28.8% vs. 8.9%; mortality, 23.1% vs. 4.3%, p<0.001).  Among the triage evaluation parameters, the only factor associated with higher mortality was the presence of clinically severe pneumonia HP neumonia MESHDon admission (Odds Ratio=12.3, 95% confidence interval=2.7-55.5, p=0.001).Conclusion: Older patients presented with more prevalent chronic comorbidities, less prevalent symptomatology but more severe respiratory signs and l aboratory abnormalities MESHDthan the younger patients. Among the triage assessment factors, the clinical evaluation of pulmonary involvement came in front to help clinicians to stratify the patients for mortality risk.

    Identification of Risk Factors for in-hospital Death of COVID - 19 Pneumonia HP

    Authors: Zhigang Wang; Zhiqiang Wang

    doi:10.21203/rs.3.rs-42478/v1 Date: 2020-07-13 Source: ResearchSquare

    Objective: To examine the clinical characteristics and identify independent risk factors for in-hospital mortality of 2019 novel coronavirus (COVID-19) pneumonia HP pneumonia MESHD.Methods: A total of 156 patients diagnosed with COVID-19 pneumonia HP pneumonia MESHD at the central Hospital of Wuhan from January 29, 2020, to March 20, 2020 were enrolled in this single-centered retrospective study. Their epidemiological parameters, clinical presentations, underlying diseases, laboratory test results and disease outcomes were collected and analyzed. Results: The median age TRANS of enrolled patients was 66. Underlying diseases were identified in 101 patients, with hypertension HP hypertension MESHD being the most common one, followed by cardiovascular disease MESHD and diabetes MESHD. The most common symptoms identified upon admission were fever HP fever MESHD, cough HP, dyspnea HP dyspnea MESHD and fatigue HP. Compared to survival cases, patients who dead during hospitalization had higher plasma SERO levels of D-dimer, creatinine, creatine kinase, lactate dehydrogenase, lactate and lower percentage of lymphocytes (LYM [%]), platelet count and albumin levels. Most enrolled patients received anti-biotics and anti-viral treatment. In addition, 60 patients received corticosteroid and 51 received intravenous immunoglobulin infusion. 44 patients received noninvasive ventilation, 19 received invasive ventilation. Respiratory failure HP Respiratory failure MESHD was the most frequently observed complication (106 [67.9%]), followed by sepsis HP sepsis MESHD (103 [66.0%]), acute respiratory distress syndrome MESHD respiratory distress HP syndrome ( ARDS MESHD) (67 [42.9%]) and septic shock MESHD shock HP (50 [32.1%]). Multivariable regression suggested that advanced age TRANS (OR [odds ratio]= 1.059, 95% CI [confidence interval]: 1.011-1.110, P= 0.016) and elevated lactate level upon admission (OR= 2.411, 95% CI: 1.177-4.941, P= 0.016) were independent risk factors for in-hospital mortality for COVID-19 infection MESHD. Meanwhile, increased LYM (%) at admission (OR= 0.798, 95% CI: 0.728-0.876, P< 0.001) indicated a better prognosis. Conclusions: In this study, we discovered that age TRANS, LYM (%) and lactate level upon admission were independent factors that could influence in-hospital mortality rate.

    In Silico Screening of Some Antiviral Phytochemicals as Drug Leads Against Covid-19

    Authors: Monjur Ahmed Laskar; Moriom Begam; Manabendra Dutta Choudhury

    doi:10.26434/chemrxiv.12478568.v1 Date: 2020-06-16 Source: ChemRxiv

    Background: COVID-19 caused by SARS-CoV-2 in December 2019 has become a pandemichazard to the community health. It is a respiratory difficulty causing fever HP, dry cough HP, fatigue HP,shortness of breath, muscle aches and some instances lead to pneumonia HP. Coronaviruses havelarge viral RNA Genomes and are single-stranded positive-sense RNA viruses. The nsp10/nsp16protein is an important target because it is essential for the virus to replicate, the papain-likeprotease (Nsp3), the main protease (Nsp5), the primary RNA-dependent RNA polymerase(Nsp12) are also attractive drug targets for this disease. The uses of phytochemicals astherapeutic agents have been increasing in recent years. Some antiviral phytochemicals weretaken based on literature survey for this study.Methods: ADME parameters and drug like nature of phytochemicals were screened usingSwissADME web tool. Three dimensional structures of targets are downloaded from ProteinData Bank and docked with phytochemicals & control by using software FlexX.Results: Morin shows significant results in ADME screening and Drug likeness predictionstudies, it shows stable bonding pattern with all four targets in compare to other phytochemicalsand control, shows least score in docking and forms maximum number of hydrogen bonds withthe active residues of the receptors.Conclusion: Based on present observation of docking results, ADME parameters and drug likenature, we suggest that morin may be a potent new drug candidate against Covid-19.Keywords: COVID-19, coronavirus, drug target, phytochemicals, Drug likeness, ADME,docking, morin

    Alarming Symptoms Leading To Severe COVID-19 Pneumonia HP: A Meta-Analysis

    Authors: Weiping Ji; Jing Zhang; Gautam Bishnu; Xudong Du; Xinxin Chen; Hui Xu; Xiaoling Guo; Zhenzhai Cai; Jun Zhang; Xian Shen

    doi:10.21203/rs.3.rs-35449/v1 Date: 2020-06-14 Source: ResearchSquare

    Background: To identify alarming symptoms that could potentially lead to severe form of COVID-19 pneumonia HP pneumonia MESHD (i.e. novel coronavirus pneumonia MESHD pneumonia HP: NCP), a disease that is now having pandemic spread.Methods: Articles from PubMed, Embase, Cochrane database and Google up to 24 February 2020 were systematically reviewed. 18 publications that had documented cases of COVID-19 pneumonia HP pneumonia MESHD were identified. The relevant data were extracted, systematically reviewed and further evaluated using meta-analysis. We define severe COVID-19 pneumonia HP pneumonia MESHD as the disease status that requires admission to the intensive care unit (ICU) and respiratory/circulatory support, which is in align with the guideline from the World Health Organization (WHO).Results: 14 studies including 1,424 patients were considered eligible and analyzed. Symptoms such as fever HP fever MESHD (89.2%), cough HP (67.2%), fatigue HP fatigue MESHD (43.6%) were quite common; but dizziness MESHD, hemoptysis HP, abdominal pain HP abdominal pain MESHD and conjunctival congestion/ conjunctivitis HP conjunctivitis MESHD were relatively rare. The incidence of dyspnea HP dyspnea MESHD was significantly higher in patients with severe than non-severe COVID-19 pneumonia HP pneumonia MESHD (42.7% vs.16.3%, p<0.0001). Similarly, fever HP fever MESHD and diarrhea HP diarrhea MESHD were also drastically more common in patients with severe form (p=0.0374 and 0.0267). Further meta-analysis using three high-quality China-based studies confirmed such findings and showed that dyspnea HP dyspnea MESHD, fever HP fever MESHD and diarrhea HP diarrhea MESHD were 3.53 (OR: 3.53, 95%CI: 1.95-6.38), 1.70 (OR: 1.70, 95%CI: 1.01-2.87), and 1.80 (OR: 1.80, 95%CI: 1.06-3.03) folds higher respectively in patients with severe COVID-19 pneumonia HP pneumonia MESHD.Conclusion: Dyspnea HP Dyspnea MESHD, fever HP and diarrhea HP diarrhea MESHD are significantly more prevalent in patients with severe COVID-19 pneumonia HP pneumonia MESHD, suggesting they are alarming symptoms that warrant close attention and timely management.

    SARS-CoV-2 Serology Results in the First COVID-19 Case in California: A Case Report and Recommendations for Serology Testing and Interpretation

    Authors: Richard B. Lanman, MD; Todd H. Lanman

    doi:10.21203/rs.3.rs-35358/v1 Date: 2020-06-12 Source: ResearchSquare

    Background: As countries in COVID-19 pandemic lockdown begin relaxation of shelter-in-place mitigation strategies, the role of serology testing escalates in importance. However, there are no clear guidelines as to when to use qualitative rapid diagnostic serology tests (RDTs) vs. SARS-CoV-2 viral RNA load (PCR) tests as an aid in acute diagnosis of patients presenting with flu-like symptoms, nor how to interpret serology test results in asymptomatic TRANS individuals or those with atypical COVID-19 symptomatology. Here we describe, in the context of the likely first case of COVID-19 in California, with an atypical presentation and not tested acutely, who nearly 3 months later was found to be IgM- and IgG+ positive for SARS-CoV-2 antibodies SERO, highlighting the role of RDT- based serology testing SERO and interpretation in retrospective diagnosis.Case Presentation: A 62-year-old male TRANS practicing neurosurgeon had onset of flu-like symptoms on January 20 with fatigue HP fatigue MESHD, slight cough HP only on deep inspiration, intermittent pleuritic chest pain MESHD chest pain HP unrelated to exertion, dyspnea HP dyspnea MESHD, and night sweats HP but without fever HP fever MESHD, sore throat or rhinorrhea HP rhinorrhea MESHD. He had recently traveled TRANS abroad but not to China. CT scan revealed right lower lobe infiltrate and effusion. Because of atypical symptoms, and low prevalence SERO of COVID-19 in January, community acquired pneumonia HP pneumonia MESHD was diagnosed and one week of doxycycline was prescribed without relief, followed by a second week of azithromycin with symptom remission. Three months later the physician-patient (author THL), tested positive for SARS-CoV-2 antibodies SERO by a serology point-of-care rapid diagnostic test (RDT).Conclusions: Serology testing may be an aid in acute diagnosis of COVID-19, especially in patients with atypical presentations, as well as in assessment of asymptomatic TRANS higher-risk persons such as healthcare workers for prior infection MESHD. Recommendations for serology testing and interpretation are explicated.

    Dose-dependent response to infection MESHD with SARS-CoV-2 in the ferret model: evidence of protection to re-challenge

    Authors: Kathryn A Ryan; Kevin R Bewley; Susan A Fotheringham; Phillip Brown; Yper Hall; Anthony C Marriott; Julia A Tree; Lauren Allen; Marilyn J Aram; Emily Brunt; Karen R Buttigieg; Breeze E Cavell; Daniel P Carter; Rebecca Cobb; Naomi S Coombes; Kerry J Godwin; Karen E Gooch; Jade Gouriet; Rachel Halkerston; Debbie J Harris; Holly E Humphries; Laura Hunter; Catherine M K Ho; Chelsea L Kennard; Stephanie Leung; Didier Ngabo; Karen L Osman; Jemma Paterson; Elizabeth J Penn; Steven T Pullen; Emma Rayner; Gillian S Slack; Kimberley Steeds; Irene Taylor; Tom Tipton; Stephen Thomas; Nadina I Wand; Robert J Watson; Nathan R Wiblin; Sue Charlton; Bassam Hallis; Julian A Hiscox; Simon Funnell; Mike J Dennis; Catherine J Whittaker; Michael G Catton; Julian Druce; Francisco J Salguero; Miles W Carroll

    doi:10.1101/2020.05.29.123810 Date: 2020-06-01 Source: bioRxiv

    In December 2019 an outbreak of coronavirus disease MESHD (COVID-19) emerged in Wuhan, China. The causative agent was subsequently identified and named severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) which rapidly spread worldwide causing a pandemic. Currently there are no licensed vaccines or therapeutics available against SARS-CoV-2 but numerous candidate vaccines are in development and repurposed drugs are being tested in the clinic. There is a vital need for authentic COVID-19 animal models to further our understanding of pathogenesis and viral spread in addition to pre-clinical evaluation of candidate interventions. Here we report a dose titration study of SARS-CoV-2 to determine the most suitable infectious dose to use in the ferret model. We show that a high (5x106 pfu) and medium (5x104 pfu) dose of SARS-CoV-2 induces consistent upper respiratory tract (URT) viral RNA shedding in both groups of six challenged animals, whilst a low dose (5x102 pfu) resulted in only one of six displaying signs of URT viral RNA replication. The URT shedding lasted up to 21 days in the high dose animals with intermittent positive signal from day 14. Sequential culls revealed distinct pathological signs of mild multifocal bronchopneumonia in approximately 5-15% of the lung, observed on day 3 in high and medium dosed animals, with presence of mild broncho-interstitial pneumonia HP on day 7 onwards. No obvious elevated temperature or signs of coughing HP or dyspnoea were observed although animals did present with a consistent post-viral fatigue HP lasting from day 9-14 in the medium and high dose groups. After virus shedding ceased, re-challenged ferrets were shown to be fully protected from acute lung pathology. The endpoints of URT viral RNA replication in addition to distinct lung pathology and post viral fatigue HP were observed most consistently in the high dose group. This ferret model of SARS-CoV-2 infection presents a mild clinical disease (as displayed by 80% of patients infected with SARS-CoV-2). In addition, intermittent viral shedding on days 14-21 parallel observations reported in a minority of clinical cases.

    Clinical Features of Hypertensive MESHD Patients With Covid-19 Compared With a Normotensive Group

    Authors: shuang wang; qiang zhang; zhao bin zheng; peng wang; hua hong ye; xiao qing jing; jun hua zhang; da yu fan; ping jia; zhong dan zhang; ting ting luo; shi sheng zhu

    doi:10.21203/rs.3.rs-31685/v1 Date: 2020-05-26 Source: ResearchSquare

    Background: The novel coronavirus (COVID-19), which began in Wuhan, China, in December 2019, has spread worldwide and poses a great threat to human health. Among COVID-19 patients, those with hypertension HP hypertension MESHD have been reported to have higher morbidity and mortality. This study was conducted to provide the international community with a deeper understanding of COVID-19 with hypertension HP hypertension MESHD.Methods: A total of 188 COVID-19 patients were studied from January to March 2020. The epidemiology, clinical features, and laboratory data of hypertensive MESHD patients with COVID-19 were collected, retrospectively analyzed, and compared with a normotensive group. The use of anti- hypertensive MESHD drugs, general treatment, and clinical outcomes of hypertensive MESHD patients were also analyzed.Results: The median ages TRANS in hypertensive MESHD patients with mild and severe COVID-19 were both significantly greater than the median age TRANS in the normotensive group. But there was no significant gender TRANS difference between the hypertensive MESHD and normotensive groups. All patients had lived in the Wuhan area. Common symptoms of all of the patients included fever HP fever MESHD, cough HP cough MESHD, and fatigue HP fatigue MESHD. Chest CT scans showed bilateral patchy shadows or ground glass opacity in the lungs of all of the patients. All (98 [100%]) of the hypertensive MESHD patients received antiviral therapy (Arbidol was used alone or in combination with Ribavirin), antibiotic therapy (85 [86.7%]), and corticosteroids (31 [31.6%]). It has been suggested that the combination of Arbidol and Ribavirin as initial therapy for hypertensive MESHD patients with COVID-19 is effective and safe. There were no significant differences in laboratory data between the mild cases in the hypertensive MESHD and the normotensive groups. In the severe cases, the hypertensive MESHD patients had higher plasma SERO levels of D-dimer, C-reactive protein (CRP), and Interleukin-6 (IL-6) (P < 0.05). Furthermore, the hypertensive MESHD patients who were treated with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) had no statistically significant differences between the mild and severe groups (p > 0.05).Conclusion: In this study, we demonstrated that the hypertensive MESHD patients who were treated with ACEI/ARB did not have an increased risk of developing severe COVID-19. Arbidol and Ribavirin played an important role in the treatment of the viral pneumonia MESHD pneumonia HP. Hypertensive MESHD patients with severe viral pneumonia HP pneumonia MESHD had stronger inflammatory responses than non- hypertensive MESHD patients.

    Identification of Risk Factors for in-Hospital Death of COVID - 19 Pneumonia HP

    Authors: Zhigang Wang; Zhiqiang Wang

    doi:10.21203/rs.3.rs-30755/v1 Date: 2020-05-21 Source: ResearchSquare

    Objective: To examine the clinical characteristics and identify independent risk factors for in-hospital mortality of 2019 novel coronavirus (COVID-19) pneumonia HP pneumonia MESHD.Methods: A total of 156 patients diagnosed with COVID-19 pneumonia HP pneumonia MESHD at the central Hospital of Wuhan from January 29, 2020, to March 20, 2020 were enrolled in this single-centered retrospective study. Their epidemiological parameters, clinical presentations, underlying diseases, laboratory test results and disease outcomes were collected and analyzed.Results: The median age TRANS of enrolled patients was 66. Underlying diseases were identified in 101 patients, with hypertension HP hypertension MESHD being the most common one, followed by cardiovascular disease MESHD and diabetes MESHD. The most common symptoms identified upon admission were fever HP fever MESHD, cough HP, dyspnea HP dyspnea MESHD and fatigue HP. Compared to survival cases, patients who dead during hospitalization had higher plasma SERO levels of D-dimer, creatinine, creatine kinase, lactate dehydrogenase, lactate and lower percentage of lymphocytes (LYM [%]), platelet count and albumin levels. Most enrolled patients received anti-biotics and anti-viral treatment. In addition, 60 patients received corticosteroid and 51 received intravenous immunoglobulin infusion. 44 patients received noninvasive ventilation, 19 received invasive ventilation. Respiratory failure HP Respiratory failure MESHD was the most frequently observed complication (106 [67.9%]), followed by sepsis HP sepsis MESHD (103 [66.0%]), acute respiratory distress syndrome MESHD respiratory distress HP syndrome ( ARDS MESHD) (67 [42.9%]) and septic shock MESHD shock HP (50 [32.1%]). Multivariable regression suggested that advanced age TRANS (OR [odds ratio]= 1.059, 95% CI [confidence interval]: 1.011-1.110, P= 0.016) and elevated lactate level upon admission (OR= 2.411, 95% CI: 1.177-4.941, P= 0.016) were independent risk factors for in-hospital mortality for COVID-19 infection MESHD. Meanwhile, increased LYM (%) at admission (OR= 0.798, 95% CI: 0.728-0.876, P< 0.001) indicated a better prognosis. Conclusions: In this study, we discovered that age TRANS, LYM (%) and lactate level upon admission were independent factors that could influence in-hospital mortality rate. 

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.